Bleakley Financial Group LLC Has $50,000 Holdings in Definitive Healthcare Corp. (NASDAQ:DH)

Bleakley Financial Group LLC cut its stake in shares of Definitive Healthcare Corp. (NASDAQ:DH) by 26.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,233 shares of the company’s stock after selling 4,415 shares during the period. Bleakley Financial Group LLC’s holdings in Definitive Healthcare were worth $50,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of DH. SG Americas Securities LLC raised its position in shares of Definitive Healthcare by 44.6% in the fourth quarter. SG Americas Securities LLC now owns 27,189 shares of the company’s stock valued at $112,000 after buying an additional 8,387 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Definitive Healthcare by 3,652.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 6,980 shares of the company’s stock worth $29,000 after buying an additional 6,794 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in shares of Definitive Healthcare by 34.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 50,886 shares of the company’s stock worth $209,000 after purchasing an additional 12,946 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Definitive Healthcare by 431.7% in the third quarter. JPMorgan Chase & Co. now owns 222,090 shares of the company’s stock worth $993,000 after purchasing an additional 180,323 shares during the last quarter. Finally, 272 Capital LP grew its stake in shares of Definitive Healthcare by 74.8% in the third quarter. 272 Capital LP now owns 1,114,080 shares of the company’s stock worth $4,980,000 after purchasing an additional 476,766 shares during the last quarter. 98.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider William Moschella sold 45,000 shares of the business’s stock in a transaction dated Tuesday, December 3rd. The shares were sold at an average price of $4.70, for a total transaction of $211,500.00. Following the transaction, the insider now owns 433,830 shares in the company, valued at $2,039,001. The trade was a 9.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.84% of the stock is owned by corporate insiders.

Definitive Healthcare Stock Performance

NASDAQ DH opened at $5.24 on Thursday. The company has a market capitalization of $605.32 million, a P/E ratio of -1.69, a P/E/G ratio of 3.94 and a beta of 1.45. The company has a fifty day moving average of $4.50 and a 200-day moving average of $4.40. Definitive Healthcare Corp. has a 52-week low of $3.19 and a 52-week high of $10.62. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.49 and a current ratio of 2.49.

Wall Street Analyst Weigh In

DH has been the topic of several analyst reports. Barclays reissued an “underweight” rating and issued a $4.00 price objective on shares of Definitive Healthcare in a research note on Monday, January 13th. Stephens started coverage on shares of Definitive Healthcare in a report on Friday, December 20th. They issued an “equal weight” rating and a $5.00 target price on the stock. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $5.72.

Definitive Healthcare Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.